Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), a purine biosynthetic enzyme. Pelitrexol also inhibits mTORC1 by reducing GTP-bound Rheb level, a mTORC1 obligate activator. Pelitrexol shows robust tumor growth suppression in mice
In Vitro
Pelitrexo (150 nM; 24 h) profoundly inhibits mTORC1 activity by reducing intracellular guanine nucleotides level as well as GTP-bound Rheb protein level in A549 cells. Pelitrexo (0-1000 mM; 16 h) strongly inhibits the phosphorylation level of ribosomal protein S6 (S6RP), S6K1, and Chk1 in a dose-dependent manner in NCI-H460 cells. Pelitrexo (100 nM; 48 h) arrests cell cycle at G1 phase in NCI-H460 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: NCI-H460 NSCLC Concentration: 100 nM Incubation Time: 4, 8, 24, 48 hours Result: Resulted 63% cells accumulation in G1 phase of the cell cycle. Cell Cycle AnalysisCell Line: NCI-H460 NSCLC Concentration: 0, 10, 30, 100, 300, 1000 nM Incubation Time: 16 hours Result: Inhibits the level of p-S6RP, p-S6K1, and p-Chk1.
In Vivo
Pelitrexo (10 mg/kg, 20 mg/kg; i.p.; every 4 days for 3 weeks) provokes both mTORC1 inhibition and robust tumor growth suppression in mice bearing nonsmall-cell lung cancer (NSCLC) xenografts . Pelitrexo (20 mg/kg; i.p.; every 4 days for 3 weeks) inhibits GARFT-dependent purine biosynthesis and blocks mTORC1 function . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft model of nonsmall-cell lung cancer (NSCLC) in mice Dosage: 10 mg/kg, 20 mg/kg Administration: Intraperitoneal injection; every 4 days for 3 weeks for group 1; administrated at 1, 4, 7 days for group 2 Result: Inhibited tumor growth by 64% and 69% at 10 mg/kg and 20 mg/kg, respectively in group 1. Inhibited mTORC1-dependent phosphorylation of S6K1, S6RP and CAD at 20 mg/kg in group 2.
IC50& Target:GARFT
사양
사양 및 순도
10mM in DMSO
생화학 및 생리적 메커니즘
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), a purine biosynthetic enzyme. Pelitrexol also inhibits mTORC1 by reducing GTP-bound Rheb level, a mTORC1 obligate activator. Pelitrexol shows robust tumor grow
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
리뷰
고객 리뷰
자주 묻는 질문
How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 446022-33-9, the molecular formula is C20H25N5O6S, and the molecular weight is 463.51 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.